ProMIS Neurosciences Overview
Latest P/E ratio for ProMIS Neurosciences: -0.62 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-0.62
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for PMN is -0.62. That is below the Healthcare sector average of 26.36. Investors often review this figure alongside ProMIS Neurosciences's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, PMN currently prints -0.62 for P/E ratio, while the sector average sits near 26.36. That is roughly 102.4% below the sector mean. Large gaps often invite a closer look at ProMIS Neurosciences's growth, margins, and balance sheet.
A P/E ratio of -0.62 for ProMIS Neurosciences is not 'good' or 'bad' on its own. Compare it with the peer average (26.36) and with PMN's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting PMN's P/E ratio (-0.62), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack ProMIS Neurosciences's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
